HIF1A and breast cancer: In 2015, Schneider et al. found that a vacuolaor-ATPase inhibitor archazolid could disrupt endocytic TFRC recycling in breast cancer cells, resulting in cellular iron depletion, which caused stabilization of the HIF1α protein, reduction of ribonucleotide reductase (RNR) activity and subsequently apoptosis in vitro and reduction of tumour growth in vivo [185].